• Home
  • Cabozantinib 80mg
  • Cabozantinib 80mg

Cabozantinib 80mg

52020

Cabozantinib is used for advanced renal cell carcinoma, either on its own after earlier treatment or with nivolumab as a first treatment.

It is used for hepatocellular carcinoma when sorafenib has already been tried.

It is also used for thyroid cancers that have spread or cannot be removed by surgery when the cancer type and previous treatments make cabozantinib appropriate.

Usual adult dose range: 20mg to 140mg once daily, depending on the cancer type, whether tablets or capsules are used, and whether cabozantinib is combined with another cancer medicine.

Indications vary by country and change over time; this website contains information for general patient information and should be checked against local prescribing information before clinical use.

Verification Approach: Each indication and usual dose-range sentence was drafted from at least two recognised medicines information sources, usually FDA/DailyMed or an FDA label plus EMA/eMC, MedlinePlus, Mayo Clinic, Cancer Research UK, NCI/ Cancer.gov, or another reputable medicines-information source. Doses are general adult/patient-information ranges and must not be used to prescribe or change treatment.
  • FDA/DailyMed prescribing information and FDA Oncology/Hematology approval notifications.
  • EMA and UK eMC Summary of Product
    Characteristics and patient leaflets where available.
  • NCI Cancer Drug Information/Cancer.gov and Cancer Research UK medicine information where available.
  • MedlinePlus, NHS/NICE, and other national medicines information for non-oncology or immune/respiratory medicines.
  • Peer-reviewed FDA approval summaries or manufacturer regulatory notices for very new, withdrawn, or region-specific
    indications.